PMID- 31083265
OWN - NLM
STAT- MEDLINE
DCOM- 20190530
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 19
DP  - 2019 May
TI  - Efficacy and safety of apatinib in treatment of osteosarcoma after failed 
      standard multimodal therapy: An observational study.
PG  - e15650
LID - 10.1097/MD.0000000000015650 [doi]
LID - e15650
AB  - Recently, apatinib has been shown to be effective in treating sarcoma. This study 
      aimed to assess the safety and efficacy of apatinib in the treatment of patients 
      with osteosarcoma after failed of standard multimodal therapy and to compare the 
      therapeutic effects of apatinib on osteosarcoma between high-dose group and 
      low-dose group.A total of 27 patients with osteosarcoma who received apatinib 
      between January 2016 and August 2017 were retrospectively reviewed. Among the 27 
      patients, the objective response rate (ORR) and the disease control rate (DCR) 
      were 25.93% and 66.67%, respectively. The median of progression-free survival 
      (m-PFS) was 3.5 months (95% confidence interval [CI], 2.5-4.8 months), and the 
      median of overall survival (m-OS) was 9.5 months (95% CI, 7.8-10.5 months). There 
      was no statistically significant difference in ORR (36.36% vs 18.75%), DCR 
      (63.64% vs 68.75%), m-PFS (4.3 months [95% CI, 1.8-7 months) vs 3.35 months (95% 
      CI, 1.8-4 months]), and m-OS (9.5 months [95% CI, 7.8-10.5 months] vs 9.4 months 
      [95% CI, 7.8-10.8 months]) (P > .05) between the high-dose group (the average 
      dose was 659 mg/qd) and the low-dose group (the average dose was 516 mg/qd). Most 
      of the adverse events (AEs) were in grade 1 or grade 2. The main AEs in grade 3 
      were hypertension, rash, weight loss, hand-foot syndrome, and diarrhea.Apatinib 
      is safe and effective in the treatment of advanced osteosarcoma. We recommend 
      that the initial dose of apatinib should be 500 mg/qd in the treatment of 
      osteosarcoma.
FAU - Tian, Zhichao
AU  - Tian Z
AD  - Department of Orthopedics.
FAU - Gu, Zhiyuan
AU  - Gu Z
AD  - Department of Orthopedics.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Orthopedics.
FAU - Liu, Zhiyong
AU  - Liu Z
AD  - Department of Orthopedics.
FAU - Yao, Weitao
AU  - Yao W
AD  - Department of Orthopedics.
FAU - Wang, Jiaqiang
AU  - Wang J
AD  - Department of Orthopedics.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Orthopedics.
FAU - Cai, Qiqing
AU  - Cai Q
AD  - Department of Orthopedics.
FAU - Ge, Hong
AU  - Ge H
AD  - Department of Radiation Oncology, The affiliated cancer hospital of Zhengzhou 
      University, Zhengzhou, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Bone Neoplasms/mortality/*therapy
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Osteosarcoma/mortality/*therapy
MH  - Pyridines/adverse effects/*therapeutic use
MH  - Retreatment
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC6531132
COIS- The authors declare that they have no competing interests. The authors have no 
      funding and conflicts of interest to disclose.
EDAT- 2019/05/15 06:00
MHDA- 2019/05/31 06:00
PMCR- 2019/05/13
CRDT- 2019/05/15 06:00
PHST- 2019/05/15 06:00 [entrez]
PHST- 2019/05/15 06:00 [pubmed]
PHST- 2019/05/31 06:00 [medline]
PHST- 2019/05/13 00:00 [pmc-release]
AID - 00005792-201905100-00117 [pii]
AID - MD-D-19-01536 [pii]
AID - 10.1097/MD.0000000000015650 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 May;98(19):e15650. doi: 10.1097/MD.0000000000015650.